Clinical and molecular characterization of thrombocytosis in transient abnormal myelopoiesis

Le résumé fourni par la source

Transient abnormal myelopoiesis (TAM) is a distinctive hematological disorder in neonates with Down syndrome, driven by somatic GATA1 mutations that promote blast proliferation [ 1 , 2 ]. Although TAM typically resolves spontaneously, a subset of patients may progress to myeloid leukemia associated with Down syndrome (ML-DS) [ 3 , 4 , 5 , 6 ]. Clinically, TAM ranges from asymptomatic cases to severe disease with multiorgan dysfunction. While thrombocytopenia is well recognized in TAM, sporadic reports of thrombocytosis [ 7 , 8 ] indicate that platelet abnormalities may be more heterogeneous than previously appreciated. In some cohorts, platelet counts have approached 1000 × 10⁹/L [ 3 , 4 ]. Whether elevated counts increase thrombosis risk, define a distinct clinical subtype, or influence disease progression has not been systematically explored. To address this gap, we conducted a secondary analysis of the TAM-10 prospective cohort, stratified by platelet count at diagnosis. We hypothesized that thrombocytosis represents a clinically and biologically distinct TAM subgroup, reflecting potential differences in underlying pathophysiology. Detailed methods are provided in the Supplementary Methods.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.